Deoxynucleoside Therapy for Thymidine Kinase 2-Deficient Myopathy.
Cristina Domínguez-González, Marcos Madruga-Garrido, Fabiola Mavillard...
https://pubmed.ncbi.nlm.nih.gov/31125140/Actively Recruiting
Led by Cristina Domínguez González · Updated on 2026-09-17
15
Participants Needed
1
Research Sites
47 weeks
Total Duration
Researchers are evaluating the effectiveness and safety of the combination of doxecitin and doxribthymine dTdC in adults with thymidine kinase 2 TK2 deficiency, a rare mitochondrial disorder causing progressive muscle weakness. This open-label, single-arm study focuses on adults with moderate to severe symptoms, including motor and respiratory involvement, who are followed at a specialized neuromuscular unit. Participants will receive oral doses of dTdC divided into three daily doses spaced about 6 to 8 hours apart. The treatment starts at 130 mgkgday per nucleoside and may be increased to 260 mgkgday after two weeks, then to a maximum of 400 mgkgday if tolerated. The study aims to enroll 10 to 15 participants who will be treated and monitored over a period of 24 months. Throughout the study, participants will visit regularly for assessments of motor function using several scales and tests, such as the Medical Research Council MRC scale, 6-minute walk test, and North Star Ambulatory Assessment. Respiratory function and use of ventilatory support will also be evaluated. Biomarkers like lactate and GDF15 will be monitored, along with safety through adverse event reporting. Treatment compliance and tolerability, especially diarrhea symptoms, will be closely observed.
CONDITIONS
Doxecitin and Doxribthymine in Adult Subjects With Thymidine Kinase 2 (TK2) Deficiency
C
Cristina Domínguez González, Dra.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Cristina Domínguez González
Lead Sponsor
UCB Pharma
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (screening and enrollment)
Duration - 24 months
Participants take oral doses of doxecitin and doxribthymine three times daily with dose increases based on tolerability. Regular assessments of muscle and respiratory function are conducted.
Visits on Day 1 and Months 1, 2, 3, 12, 15, 18, 21, and 24
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Cristina Domínguez-González, Marcos Madruga-Garrido, Fabiola Mavillard...
https://pubmed.ncbi.nlm.nih.gov/31125140/Andres Berardo, Cristina Domínguez-González, Kristin Engelstad...
https://pubmed.ncbi.nlm.nih.gov/35094997/Laura Bermejo-Guerrero, Ana Hernández-Voth, Pablo Serrano-Lorenzo...
https://pubmed.ncbi.nlm.nih.gov/38599303/Cristina Dominguez-Gonzalez, Carmen Badosa, Marcos Madruga-Garrido...
https://pubmed.ncbi.nlm.nih.gov/32572108/Cristina Domínguez González
Lead Sponsor
UCB Pharma
Collaborating Sponsor